PFIZER INC 4

4 · PFIZER INC · Filed Feb 27, 2017

Form 4

Period: 2017-02-23

Executive Vice President

Transactions

Exercise/Conversion
Common Stock
2017-02-23$21.03/sh+21,238$446,635→ 33,848 total
Tax Payment
Common Stock
2017-02-23$34.06/sh−3,837$130,688→ 30,011 total
Tax Payment
Common Stock
2017-02-23$32.49/sh−10,282$334,062→ 19,729 total
Exercise/Conversion
Stock Appreciation Rights
2017-02-23−21,238→ 0 total
Exercise: $21.03From: 2017-02-23Exp: 2017-02-23→ Common Stock (21,238 underlying)
Award
Stock Appreciation Rights
2017-02-23+32,468→ 32,468 total
Exercise: $34.06From: 2022-02-23Exp: 2022-02-23→ Common Stock (32,468 underlying)
Award
Stock Appreciation Rights
2017-02-23+26,954→ 26,954 total
Exercise: $34.06From: 2024-02-23Exp: 2024-02-23→ Common Stock (26,954 underlying)

Footnotes (6)

[F1]The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
[F2]The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
[F3]The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
[F4]Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
[F5]The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
[F6]The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

Documents

1 file